Prime Medicine, Common Etf Beta
| PRME Etf | USD 3.33 0.13 4.06% |
Prime Medicine, Common fundamentals help investors to digest information that contributes to Prime Medicine,'s financial success or failures. It also enables traders to predict the movement of Prime Etf. The fundamental analysis module provides a way to measure Prime Medicine,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prime Medicine, etf.
Prime |
Prime Medicine, Common ETF Beta Analysis
Prime Medicine,'s Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Prime Medicine, Beta | 2.09 |
Most of Prime Medicine,'s fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prime Medicine, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Prime Medicine, Common has a Beta of 2.093. This is much higher than that of the Biotechnology family and significantly higher than that of the Health Care category. The beta for all United States etfs is notably lower than that of the firm.
Prime Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prime Medicine,'s direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Prime Medicine, could also be used in its relative valuation, which is a method of valuing Prime Medicine, by comparing valuation metrics of similar companies.Prime Medicine, is currently under evaluation in beta as compared to similar ETFs.
Prime Medicine, Institutional Holders
Institutional Holdings refers to the ownership stake in Prime Medicine, that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Prime Medicine,'s outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Prime Medicine,'s value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Millennium Management Llc | 2024-06-30 | 1.3 M | State Street Corp | 2024-06-30 | 1.1 M | Baker Bros Advisors Lp | 2024-09-30 | 1 M | Deerfield Management Co | 2024-09-30 | 897 K | Farallon Capital Management, L.l.c. | 2024-09-30 | 750 K | Greenwich Wealth Management Llc | 2024-09-30 | 733 K | Ecor1 Capital, Llc | 2024-09-30 | 700 K | Avidity Partners Management Lp | 2024-09-30 | 694 K | Alphabet Inc | 2024-09-30 | 15.1 M | Ark Investment Management Llc | 2024-09-30 | 5.7 M |
Fund Asset Allocation for Prime Medicine,
The fund invests 99.55% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Prime Medicine,'s investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prime Medicine, will likely underperform.
Prime Fundamentals
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (259.48) % | ||||
| Current Valuation | 285.44 M | ||||
| Shares Outstanding | 131.16 M | ||||
| Shares Owned By Insiders | 23.90 % | ||||
| Shares Owned By Institutions | 62.31 % | ||||
| Number Of Shares Shorted | 15.79 M | ||||
| Price To Earning | 14.40 X | ||||
| Price To Book | 2.21 X | ||||
| Price To Sales | 524.64 X | ||||
| Gross Profit | (86.72 M) | ||||
| EBITDA | (193.76 M) | ||||
| Net Income | (198.13 M) | ||||
| Cash And Equivalents | 146.66 M | ||||
| Cash Per Share | 6.39 X | ||||
| Total Debt | 13.63 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 6.70 X | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | (165.41 M) | ||||
| Short Ratio | 5.78 X | ||||
| Earnings Per Share | (2.06) X | ||||
| Target Price | 12.64 | ||||
| Number Of Employees | 234 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 419.72 M | ||||
| Total Asset | 193.85 M | ||||
| Retained Earnings | (491.33 M) | ||||
| Working Capital | 86.55 M | ||||
| One Year Return | (0.31) % | ||||
| Three Year Return | 3.82 % | ||||
| Net Asset | 193.85 M | ||||
| Equity Positions Weight | 99.55 % |
About Prime Medicine, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prime Medicine, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prime Medicine, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prime Medicine, Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.